MindRank, a Hangzhou drug developer built around AI, says its lead candidate went from programme initiation to Phase III trials in roughly four and a half years on about $23mn of cumulative research spending. If that holds up, it is the most concrete answer yet to a question the sector has been asking loudly and […]<br /> This story continues at The Next Web [...]
An NYU professor ran oral exams using a voice AI agent. The experiment cost $15 for 36 students and revealed not just gaps in student knowledge, but weaknesses in his own teaching.<br /> The art [...]
Across 101 enterprises, the infrastructure that feeds AI agents their business context is being built faster than it can be trusted. Retrieval-augmented generation is already the default context sourc [...]
Drug discovery is notoriously inefficient. Pharmaceutical projects span years, moving from one specialized human team to the next through disconnected workflows that result in knowledge loss during ea [...]
Music hardware and software manufacturer Native Instruments has entered into preliminary insolvency proceedings, according to a report by Create Digital Music. This is the company behind iconic softwa [...]
Cheaper pharmaceuticals won’t be on shelves any time soon, says the CEO of Pfizer. That’s despite an executive order signed last month declaring a war on drug prices, which at one point President [...]
Presented by MongoDBThe gap between what AI models and agents can produce and what legacy infrastructure can reliably support is known as architectural drag, and it is the defining bottleneck of the a [...]
For the past year, enterprise decision-makers have faced a rigid architectural trade-off in voice AI: adopt a "Native" speech-to-speech (S2S) model for speed and emotional fidelity, or stick [...]